MarketScreener Homepage > Equities > Euronext Paris > GenSight Biologics S.A. SIGHT FR0013183985

Report

Real-time Euronext Paris - 01/15 11:35:12 am
8.25	EUR		-1.08%

01/14

GENSIGHT BIOLOGICS S A : - ESSA Pharma Announces Clinical Collaboration with Janssen to Evaluate EPI-7386 Combination for Patients with Metastatic Castration-Resistant Prostate Cancer

01/13

GENSIGHT BIOLOGICS S A : Expects EU Decision on Eye Disorder Drug Lumevoq in Q4

01/13

GENSIGHT BIOLOGICS : Announces Publication of Results from LUMEVOQ® RESCUE Pivotal Phase III Trial in AAO journal Ophthalmology®

Summary

Quotes 5-day view Real-time Quote.

Real-time Euronext Paris

01/11/2021	01/12/2021	01/13/2021	01/14/2021	01/15/2021	Date
7.5(c)	8.62(c)	8.33(c)	8.34(c)	8.25(c)	Last
480 513	1 445 890	651 743	286 543	333 181	Volume
+1.63%	+14.93%	-3.36%	+0.12%	-1.08%	Change

More quotes

Financials

Sales 2020	11,5 M 13,8 M 13,8 M
Net income 2020	-19,6 M -23,7 M -23,7 M
Net cash position 2020	6,05 M 7,31 M 7,31 M
P/E ratio 2020	-14,5x
Yield 2020	-

Sales 2021	15,0 M 18,1 M 18,1 M
Net income 2021	-14,1 M -17,0 M -17,0 M
Net Debt 2021	12,4 M 15,0 M 15,0 M
P/E ratio 2021	-23,1x
Yield 2021	-

Capitalization	352 M 426 M 425 M
EV / Sales 2020	30,2x
EV / Sales 2021	24,4x
Nbr of Employees	25
Free-Float	95,4%

More Financials

Company

GenSight Biologics S.A. specializes in the research and development of gene therapies for the treatment of mitochondrial diseases and eye neurodegeneratives. At the end of 2019, the company had a portfolio of 2 products, including 1 in phase III clinical development (GS010 for the treatment of Leber's hereditary optic neuropathy) and 1 in phase I/II clinical development (GS030 for the treatment of retinitis...

Sector

Biotechnology & Medical Research

Calendar

01/19

Sales and Revenue Release

More about the company

Notations Surperformance© of GenSight Biologics S.A.

Trading Rating :

Investor Rating :

More Ratings

All news about GENSIGHT BIOLOGICS S.A.

01/14	GENSIGHT BIOLOGICS S A : - ESSA Pharma Announces Clinical Collaboration with Jan..	AQ
01/13	GENSIGHT BIOLOGICS S A : Expects EU Decision on Eye Disorder Drug Lumevoq in Q4	MT
01/13	GENSIGHT BIOLOGICS : Announces Publication of Results from LUMEVOQ® RESCUE Pivot..	BU
2020	GENSIGHT BIOLOGICS S A : Announces Publication of Results from LUMEVOQ REVERSE P..	AQ
2020	GENSIGHT BIOLOGICS : Announces the Partial Conversion of Convertible Bonds and F..	BU
2020	GENSIGHT BIOLOGICS : Announces Publication of Results from LUMEVOQ® REVERSE Pivo..	BU
2020	GENSIGHT BIOLOGICS S A : reports validation of LUMEVOQ Marketing Authorisation A..	AQ
2020	GENSIGHT BIOLOGICS S A : reports validation of LUMEVOQ® Marketing Authorisation ..	PU
2020	GENSIGHT BIOLOGICS : Reports Validation of LUMEVOQ® Marketing Authorisation Appl..	BU
2020	GENSIGHT BIOLOGICS S A : successfully raises EUR25 million in an oversubscribed ..	AQ
2020	GENSIGHT BIOLOGICS S A : Securities Note	PU
2020	GENSIGHT BIOLOGICS S A : Amendment to the 2019 Universal Registration Document	PU
2020	GENSIGHT BIOLOGICS S A : launches a capital increase of approximately EUR25 mill..	AQ
2020	GENSIGHT BIOLOGICS S A : successfully raises €25 million in an oversubscribed pr..	PU
2020	GENSIGHT BIOLOGICS S A : Successfully Raises €25 Million in an Oversubscribed Pr..	BU

More news

News in other languages on GENSIGHT BIOLOGICS S.A.

01/13	Washington attend la curée
01/13	EN DIRECT DES MARCHES : Carrefour, Total, TechnipFMC, Valneva, Esker, Boeing, Vi..
01/13	GENSIGHT BIOLOGICS : annonce la publication dans la revue Ophthalmology® des rés..
2020	Quand le sage montre la lune, l'idiot regarde le doigt
2020	EN DIRECT DES MARCHES : ArcelorMittal, Kering, Sanofi, Solutions 30, Innate, Air..

More news

Provided by Scoopnest.com

Chart GENSIGHT BIOLOGICS S.A.

Duration : Period :

GenSight Biologics S.A. Technical Analysis Chart | SIGHT | FR0013183985 | MarketScreener

Full-screen chart

Technical analysis trends GENSIGHT BIOLOGICS S.A.

	Short Term	Mid-Term	Long Term
Trends	Bullish	Bullish	Bullish

Technical analysis

Income Statement Evolution

More Financials

Consensus

Sell

Buy

Mean consensus	BUY
Number of Analysts	3
Average target price	13,00 €
Last Close Price	8,25 €
Spread / Highest target	81,8%
Spread / Average Target	57,6%
Spread / Lowest Target	21,2%

Consensus

EPS Revisions

More Estimates Revisions

Managers and Directors

Name	Title
Bernard Jacques Alex Gilly	Chief Executive Officer & Director
Michael S. Wyzga	Chairman
Thomas Gidoin	Chief Financial Officer
Magali Taiel	Chief Medical Officer
José-Alain Sahel	Director

More about the company

Sector and Competitors

	1st jan.	Capitalization (M$)

GENSIGHT BIOLOGICS S.A.	15.71%	426



GILEAD SCIENCES, INC.	8.70%	78 220
VERTEX PHARMACEUTICALS	-4.57%	58 800
REGENERON PHARMACEUTICALS	7.21%	54 663
WUXI APPTEC CO., LTD.	3.52%	53 415
BEIGENE, LTD.	33.52%	30 634

More Results